Sondos Zayed (@SondosZayedMD) header
Sondos Zayed (@SondosZayedMD) profile picture

MD | Radiation Oncologist | The Ottawa Hospital | #WomenWhoCurie | Public Health & Gender Equity advocate | Tweets = Own views | 2023 #WXNTop100

Ontario, Canada
Joined August 2019
Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)Photo by Sondos Zayed (@SondosZayedMD)
Highly practical ESTRO guidelines. Re-RT for locally recurrent rectal cancer should no longer be the "exception." W thoughtful planning, re-RT (often 30–40 Gy BID, w SBRT in select cases) can safely 1) improve resectability, 2) definitively tx or 3) palliate symptoms. @OncoAlert
7
53
2
103
8,673
Sondos Zayed retweeted
“Are oligometastatic cancers curable? And should patients with oligometastatic cancers be treated aggressively with ablative treatments?” @drdavidpalma ascopubs.org/doi/10.1200/JCO…
4
18
2
56
11,097
Sondos Zayed retweeted
RASolute 302 : Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer buff.ly/kw22hZ2 In this phase 3 trial of 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma, the oral RAS(ON) inhibitor daraxonrasib significantly improved outcomes versus investigator’s-choice chemotherapy🧪 . Median overall survival doubled (13.2 vs. 6.6–6.7 months), while progression-free survival also improved 📈 substantially (7.2–7.3 vs. 3.5–3.6 months). Benefits were consistent across populations, including RAS G12-mutant disease. Daraxonrasib demonstrated a manageable safety profile, with fewer treatment discontinuations than chemotherapy. #PancreaticCancer @EileenMOReilly @WainbergZev @DrHendifar @MiteshBorad @FilippoPietran4 @DrShubhamPant @ChiaraCrem1 @DrGManji @md_oberstein @GarridoLagunaMD @pashtoonkasi @CathyEngMD @marklewismd @manjuggm @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen @graokane
3
39
2
111
5,396
SBRT (50Gy/5fx, MR adaptive) in locally recurrent PDAC. N=46 (7 w prior RT). 1 year LC 73%, median OS 19 mo. Ablative RT = feasible, safe in locally recurrent setting & can confer long term dz control. Great to see this data published - congrats @adapthyun & team! @OncoAlert
New in #practicalRO: Adaptive Salvage Stereotactic Radiation for Locoregional Recurrence of Pancreatic Adenocarcinoma After Surgery. #radonc tinyurl.com/prolakomy
3
21
1
65
9,601
What are the outcomes associated w/ re-irradiation for meningiomas? This systematic review and meta-analysis identified 16 studies with 385 pts who received re-☢️ for meningioma. 🔘 Median time from initial RT: 38 mo 🔘 Re-☢️ techniques used: SRS (43%), FSRT (21%), particle therapy (28%) 🔘 Pooled rate of Local Control: 53% (95% CI 48-58%) 🔘 Pooled rate of Overall Survival: 73% (95% CI 67-78%) 🔘 Pooled rate of Symptomatic RT Necrosis: 8% (95% CI 5-11%) 🔘 Pooled rate of Acute Toxicity: 22% (95% CI 17-28%) 🔘 Pooled rate of Chronic Toxicity: 16% (95% CI 11-21%) 🔗 - tinyurl.com/4s2jdw2z @ASTRO_org #radonc #bcsm
6
17
1,460
Announcing Vol 1 of the #SBRT special issue! Issue online at: redjournal.org/issue/S0360-3… Podcast with host @drdavidpalma at: redjournal.org/audio-do/red-… also Apple, Spotify, YouTube, Buzzsprout @machealthsci @FabArcidiacono8 @BCCancer @karolinskainst
23
3
39
4,890
Sondos Zayed retweeted
Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image). Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.1056/NE…
1
58
3
137
15,646
Want to try Sim-Free RT for palliative cases? Some recommendations here, led by @Melissa_O_Neil ⬇️⬇️⬇️
So thrilled to have led this 🌍🌏🌎 international Delphi project with the pioneers of #simfreeRT. 📣 Consensus guidelines for clinical implementation of non-adaptive sim-free RT now available in AdvRadOnc! ➡️ doi.org/10.1016/j.adro.2025.…
18
58
6,515
Here's a new RCT led by our PGY-5 resident @drviviantan, called PPI-PROTECT! 👇👇👇
Excited to accrue the first patient on PPI-PROTECT 🛡️ This is a pragmatic randomized 1:1 clinical trial investigating the role of prophylactic PPI to prevent esophagitis in #lungcancer patients undergoing radiation 🫁☢️ #radonc #oncology #medtwitter
1
5
34
4,049
🌟🚨 CATNON final results – Practice-changing data Concurrent + adjuvant temozolomide in 1p/19q non-codeleted anaplastic glioma (EORTC 26053-22054 | The @TheLancet Oncology) 🔹 Key results ✔️ Overall survival benefit with adjuvant temozolomide ❌ No OS benefit from concurrent temozolomide alone 🧬 IDH-mutant tumors derive the greatest benefit 📊 Long-term follow-up confirms durability of effect 🔹 Why this matters • Establishes adjuvant TMZ as the critical component • Refines treatment sequencing in WHO grade 3 glioma • Supports molecular stratification (IDH status) in decision-making • Direct impact on daily neuro-oncology practice @DrNeuroOnc @RishiLullaMD @DrPrados @WellerMichael @robertjenkinsmd @DrKesari @joergchristiant @NaderSanai thelancet.com/journals/lanon…
2
13
1
37
1,768
Great presentation on advancements in RT for liver metastases. Ablative RT can be curative, non-invasive, & efficient. No better person than @MikeChuongMD to highlight the evolution & potential of innovative RT technologies in this space. #GI26
38
1
123
5,221
Sondos Zayed retweeted
Art of Oncology The Power of “I Don’t Know” @JCO_ASCO doi.org/10.1200/JCO-25-02489 😄I fully agree... @myESMO
3
41
4
190
14,653
SOFT study: 141 elderly (70+), chemo-ineligible pts w locally advanced rectal cancer. Short-course RT → delayed surgery achieved 94% R0 resection & 5% local recurrence. A v reasonable, low-burden strategy for older pts w competing risks. @OncoAlert sciencedirect.com/science/ar…
4
62
1
140
9,690
Does organ preservation after cCR with TNT🧨 affect distant metasases rate in rectal ca? Results of NO-CUT🚫🔪trial @TheLancetOncol show 26% of pMMR/MSS pts achieve cCR and distant RFS 95% in nonop group vs 74% SOC @OHSUKnight @tsikitis @HKennecke sciencedirect.com/science/ar…
4
50
1
128
28,295
Sondos Zayed retweeted
New today in #PracticalRO: First clinical guideline from ASTRO focusing on radiation therapy for patients with gastric (stomach) cancer. Recommendations outline radiation therapy’s role in multidisciplinary care. #RadOnc #GastricCancer #StomachCancer ow.ly/AFwV50XtM8Z
1
20
2
37
5,891
Big news: the Anatomy and Radiology Contouring Bootcamp is now FREE! 🧵🧵🧵with photos of your attendings when they were residents... arcbootcamp.com
2
45
7
124
8,288
Sondos Zayed retweeted
Celiac plexus ablation⚡️! Never seen one? Check out how it's done and maybe suggest it next time for your pancreas patient with intractable pain! econtour.org/cases/172 And you know it's good cuz @NiuSanford reviewed the case! Thanks Peter Lee, MD @FoxChaseCancer for the case
1
13
1
36
9,186
Sondos Zayed retweeted
Review your pancreas "Triangle Volume" with this great case, submitted by Serena Moa, MD, PhD from @JohnsHopkins w/ special shout-out to @MikeChuongMD for reviewing! PS: don't forget to check out the dose constraints for this SBRT case! econtour.org/cases/168
13
37
2,641
Thanks to @MikeChuongMD for a masterclass on ablative pancreas RT! Agree we are just seeing tip of iceberg for settings where ablative RT can improve OS or QOL in pancreas cancer. 🤞 for additional studies assessing expanding indications as summarized below. #ASTRO25
1
18
1
53
3,987
It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in @TheLancetOncol Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR ⚖️ No difference in overall survival 😰 Serious adverse events 40% 👍 Both regimens may be considered thelancet.com/journals/lanon…
5
83
4
172
24,602